Cases of pneumonia caused by severe acute respiratory syndrome coronavirus 2 were first described in Wuhan, China, at the end of December 2019 (1). The infection rapidly spread, causing the coronavirus disease (COVID-19) pandemic (2).

Because SARS-CoV-2 and treatments such as dexamethasone or tocilizumab can impair the immune system, some researchers anticipated the possibility of fungal superinfection among COVID-19 patients (3–6). As of August 2020, researchers have documented COVID-19–associated pulmonary aspergillosis (CAPA) (7–9), invasive candidiasis (10), coccidioidomycosis (11), fusariosis (12), histoplasmosis (13), mucormycosis (14), pneumocystosis (15), and saccharomycosis (16). Varying cumulative rates of CAPA have been described, including rates of 0.7%–7.7% among COVID-19 patients (17, 18), 2.5%–39.1% among ICU patients with COVID-19 (19, 20), and 3.2%–29.6% among COVID-19 patients on mechanical

Pneumonia caused by severe acute respiratory syndrome coronavirus 2 emerged in China at the end of 2019. Because of the severe immunomodulation and lymphocyte depletion caused by this virus and the subsequent administration of drugs directed at the immune system, we anticipated that patients might experience fungal superinfection. We collected data from 186 patients who had coronavirus disease–associated pulmonary aspergillosis (CAPA) worldwide during March–August 2020. Overall, 182 patients were admitted to the intensive care unit (ICU), including 180 with acute respiratory distress syndrome and 175 who received mechanical ventilation. CAPA was diagnosed a median of 10 days after coronavirus disease diagnosis. Aspergillus fumigatus was identified in 80.3% of patient cultures, 4 of which were azole-resistant. Most (52.7%) patients received voriconazole. In total, 52.2% of patients died; of the deaths, 33.0% were attributed to CAPA. We found that the cumulative incidence of CAPA in the ICU ranged from 1.0% to 39.1%.

Author affiliations: University of Cologne, Cologne, Germany (J. Salmanton-García, R. Sprute, J. Stemler, E. Sal, X. Malaj, D. Seidel, O.A. Cornely, P. Koehler); L’Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola, Bologna, Italy (M. Bartoletti); Alma Mater Studiorum University of Bologna, Bologna (M. Bartoletti); Hospices Civils de Lyon, Lyon, France (D. Dupont); Université Claude Bernard Lyon 1, Lyon (D. Dupont); Centre de Recherche en Neurosciences de Lyon, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Lyon (D. Dupont); Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (M. Valerio, M. Machado, S. de la Villa); Hospital Clinic, Institute of Biomedical Research August Pi i Sunyer, Barcelona, Spain (C. García-Vidal); Hospital Universitario La Paz, Madrid (I. Falces-Romero); University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M. Schroeder); Centro Médico ABC, Mexico City, Mexico (I. Hoyo); University Hospital Regensburg, Regensburg, Germany (F. Hanses); Federal University of Triângulo Mineiro, Uberaba, Brazil (K. Ferreira-Paim); Istituto di Ricovero e Cura a Carattere Scientifico San Martino Polyclinic Hospital, Genoa, Italy (D.R. Giacobbe); Canisius Wilhelmina Hospital, Nijmegen, the Netherlands (J.F. Meis); Federal University of Paraná, Curitiba, Brazil (J.F. Meis); University of Rennes I, Institut National de la Santé et de la Recherche Médicale, École des Hautes Études en Santé Publique, Institut de Recherche en Santé, Environnement et Travail, Rennes, France (J.-P. Gangneux); Hospital de Cabueñes, Gijón, Spain (A. Rodríguez-Guardado); Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain (A. Rodríguez-Guardado); University of Milan, Milan, Italy (S. Antinori); German Centre for Infection Research, Cologne (O.A. Cornely)

DOI: https://doi.org/10.3201/eid2704.204895

1These senior authors contributed equally to this article.
2Members of this group are listed at the end of this article.
Many of these patients lack the concurrent conditions usually associated with invasive pulmonary aspergillosis (IPA) such as malignancies, neutropenia, or history of allogeneic stem cell or solid organ transplantation (21). Admission to the ICU or severe influenza are also risk factors for IPA in non-neutropenic patients (22–25). Reports of CAPA have been mostly limited to a few single-center studies; therefore, a comprehensive analysis of international distribution currently is lacking (4).

We analyzed reports in the literature (26–50; references 51–54 in Appendix, https://wwwnc.cdc.gov/EID/article/27/4/20-4895-App1.pdf) and the FungiScope registry (reference 55 in Appendix) to describe baseline conditions, clinical management, and associated deaths in CAPA patients. This analysis also contextualizes the available cumulative incidences.

**Methods**

We conducted a retrospective analysis using clinical data of patients worldwide who received a CAPA diagnosis during March 1–August 31, 2020. Our analysis comprised data from the FungiScope registry and academic literature (Figure 1).

FungiScope (https://www.clinicaltrials.gov; National Clinical Trials identifier NCT01731353) is a global registry for emerging invasive fungal infections. FungiScope was approved by the local ethics committee of the University of Cologne, Cologne, Germany (study ID 05-102). The registry includes patients with invasive aspergillosis since 2019. FungiScope’s methods have been described previously (reference 55 in Appendix).

In addition, we conducted a literature search using the PubMed database (https://pubmed.ncbi.nlm.nih.gov) for suspected CAPA cases occurring in March–August 2020. We used the search string “(Aspergillus*) AND (invasive OR putative OR probable OR infection OR case OR patient OR report) AND (COVID* OR corona* OR SARS-CoV-2),” which identified 59 published articles. We reviewed and extracted relevant data from each of the publications. When necessary, we contacted authors for additional details (Appendix).

**Figure 1.** Enrollment process in study of patients with CAPA, March–August 2020. Patients were identified in the FungiScope registry and academic literature using the search string “(Aspergillus*) AND (invasive OR putative OR probable OR infection OR case OR patient OR report) AND (COVID* OR corona* OR SARS-CoV-2) (Appendix Table 1, https://wwwnc.cdc.gov/EID/article/27/4/20-4895-App1.pdf). The initial 288 COVID-19 patients suspected to have IA were revised in a deduplication process; 59 double entries were identified. Only 1 report per patient was maintained. Thus, 221 individual COVID-19 patients suspected to have IA were assessed for CAPA. CAPA, COVID-19–associated pulmonary aspergillosis; COVID-19, coronavirus disease; EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycoses Study Group; IA, invasive aspergillosis.
We reviewed each patient report using multiple diagnostic definitions. First, we evaluated the patients according to the consensus definition of Koehler et al. (reference 56 in Appendix); we classified the patients as having proven, probable, or possible CAPA. We used alternative definitions to evaluate patients who were nonclassifiable because of lack of essential information, such as the volume of saline recovered by nondirected bronchial lavage (NBL) fluid applied. We categorized the nonclassifiable patients as proven or probable according to the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group criteria for invasive fungal infections (21) or as proven, putative, and colonized according to the AspiICU algorithm for IPA in critically ill ICU patients by Blot et al. (23). We considered severe COVID-19 with acute respiratory distress syndrome (ARDS) to be a valid host criterion (i.e., acquired immunodeficiency) (8). We considered patients who met ≥1 definition to have CAPA; we categorized the rest as nonclassifiable.

We collected data on patients’ demographic characteristics and baseline conditions. We also collected data on abnormal radiographic images, mycologic evidence, signs and symptoms at CAPA diagnosis, site of infection, antifungal susceptibility testing, antifungal treatment, death at 6 and 12 weeks after CAPA diagnosis, and absolute death. In addition, we calculated the length of time between COVID-19 and CAPA diagnoses, CAPA diagnosis and most recent healthcare contact with the patient, ICU admission and CAPA diagnosis, and installation of mechanical ventilation and CAPA diagnosis. The contribution of CAPA to patient death (i.e., attributable mortality) was assessed by the treating medical team (Appendix Table 2). To determine the cumulative incidence of CAPA in the facilities included in the analysis, we asked each institution for 3 different denominators: the total number of COVID-19 patients, the number of COVID-19 patients admitted to the ICU, and the number of COVID-19 patients admitted to the ICU who needed mechanical ventilation during March–August 2020.

Statistical Analysis
We did not calculate an a priori sample size for this exploratory study. To analyze the demographic and clinical characteristics of patients with CAPA, we describe categorical variables using frequencies and percentages; we describe continuous variables using medians and interquartile ranges (IQRs). We used SPSS Statistics 25.0 (IBM, https://www.ibm.com) for statistical analyses.

Results
We identified 186 CAPA cases during March 1–August 31, 2020, in 17 different countries, according to European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group criteria (21), Blot et al. algorithm (23), and Koehler et al. consensus definition (reference 56 in Appendix) (Figures 1, 2; Appendix Table 1). We identified 62 (33.3%) cases from literature, 45 (24.2%) from the FungiScope registry, and an additional 79 (42.5%) in both sources (Table 1). The median age among persons with CAPA was 68 years (IQR 59–73 years; range 15–87 years). Most (135; 72.6%) patients were men (Table 2).

Nearly all (182; 97.8%) patients were admitted to the ICU, most for ARDS (180; 96.8%) or mechanical ventilation (175; 94.1%). Other common baseline conditions and characteristics included corticosteroid administration (98; 52.7%), chronic cardiovascular disease (94; 50.5%), renal failure (74; 39.8%), diabetes mellitus (64; 34.4%), and obesity (47; 25.3%). Overall, 40 (21.5%) patients had chronic pulmonary disease (Table 2).

In total, 110 (59.1%) patients received either hydroxychloroquine (98; 52.7%) or chloroquine (12; 6.5%) for treatment of COVID-19. Sixty-eight (36.6%) patients received corticosteroids, mainly methylprednisolone monotherapy (26; 14.0%) or antivirals (67; 36.0%), especially lopinavir/ritonavir monotherapy (56; 30.1%). COVID-19 treatment had a median duration of 7 days before recovery or death (IQR 6–11 days; range 1–32 days) (Table 2; Appendix Table 3).

In 152 (81.7%) patients, CAPA was diagnosed a median of 10 days (IQR 5–16 days; range 0–51 days) after a positive respiratory sample for SARS-CoV-2 infection by reverse transcription PCR. Among all patients, *Aspergillus fumigatus* was the most frequently reported (122/152; 65.6%) pathogen. Six patients (3.2%) had cultures positive for >1 *Aspergillus* species. Samples mainly were from bronchoalveolar lavage (BAL) (50; 26.9%), tracheal aspirates (48; 25.8%), or bronchial aspirates (34; 18.3%). In 55 (29.6%) patients, culture was the only diagnostic tool that produced a positive result. Galactomannan (GM) levels were positive (i.e., optical density index ≥1.0) in samples from 113 (60.8%) patients, including BAL samples from 63 (33.9%) patients, serum or plasma from 29 (15.6%), and NBL from 22 (11.8%). Histologic techniques were used for diagnosis in 7
Abnormal radiographic imaging was found in 182 (97.8%) patients, either in computed tomography scans (94; 50.5%), in chest radiographs (48; 25.8%), or both (40; 21.5%) (Table 2).

Overall, 30 (16.1%) patients provided samples for ≥1 antifungal susceptibility test, such as microdilution according to European Committee on Antimicrobial Susceptibility Testing guidelines (20; 10.8%) (reference 57 in Appendix), Etest (11; 5.9%), and Clinical and Laboratory Standards Institute microdilution procedures (1; 0.5%) (reference 58 in Appendix). The tests were predominantly performed on *A. fumigatus* (29; 15.6%) isolates, 3 of which had the TR34L98H resistance mutation in the cyp51A gene. One (0.5%) patient had voriconazole-resistant *A. lentulus* (MIC 2 µg/mL by EUCAST guidelines) (Appendix Table 4).

Of 186 CAPA patients, 49 (26.3%) patients did not receive mold-active antifungal therapy. The most common treatments were triazoles (117; 62.9%), especially voriconazole (98; 52.7%, including 79 patients for whom voriconazole was a first-line treatment) and isavuconazole (23; 12.4%). In total, 34 (19.4%) patients received amphotericin B, especially liposomal amphotericin B (23; 12.4%). Of the patients who received amphotericin B, 15 (65.2%) received it as first-line treatment. Antifungal treatment was administered for a median of 16 days before recovery or death (IQR 10–33 days; range 1–92 days) (Table 2; Appendix Table 5).

In total, 97 (52.2%) patients died, most (89; 47.8%) ≤6 weeks after CAPA diagnosis. In 32 (17.2%) patients, death was attributed to *Aspergillus*; including 25 (13.4%) patients who died of aspergillosis and COVID-19 infection. Patients were observed for a median of 22 days (IQR 7–42 days; range 0–144 days) after CAPA diagnosis; survivors were treated for a median of 40 days (IQR 28–50 days; range 1–144 days) and patients who died for a median of 9 days (IQR 3–18 days; range 0–144 days) (Table 2).

In total, 19 of 39 institutions provided denominators for cumulative incidence over the duration of the study period. The CAPA incidence among all COVID-19 patients ranged from 0.1%–9.7%. Among COVID-19 patients admitted to ICU, cumulative incidences ranged from 1.0%–39.1%. Among patients admitted to ICU who needed mechanical ventilation, cumulative incidences ranged from 1.1%–47.4% (Table 3).

**Discussion**

We described 62 CAPA cases in the literature, 45 in the FungiScope registry, and 79 in both that were diagnosed during March 1–August 31, 2020. Men had a higher (2.6:1) prevalence of CAPA than women. This finding corresponds with a meta-analysis of >3 million COVID-19 patients that showed that men were at increased risk for severe COVID-19.
and therefore complications such as CAPA (reference 59 in Appendix).

### Table 1. Pathogens of 186 patients with coronavirus disease–associated pulmonary aspergillosis, March–August 2020*

| Characteristic | No. (%) |
|----------------|---------|
| Pathogens†     |         |
| *Aspergillus fumigatus*              | 122 (65.6) |
| A. niger                           | 13 (7.0)   |
| A. flavus                          | 10 (5.4)   |
| A. terreus                         | 6 (3.2)    |
| A. calidoustus                     | 1 (0.5)    |
| A. lentulus                        | 1 (0.5)    |
| A. nidulans                        | 1 (0.5)    |
| A. penicilliodes                   | 1 (0.5)    |
| A. versicolor                      | 1 (0.5)    |
| A. tubingensis                     | 1 (0.5)    |
| Aspergillus spp. (culture)‡        | 1 (0.5)    |
| Aspergillus spp. (serologic techniques)§  | 34 (18.3) |
| Other pathogens§                   | 40 (21.5)  |

Case definition

- EORTC/MSG criteria (21): Proven 7 (3.8), Probable 10 (5.4), Nonclassifiable 169 (90.9).
- AspICU algorithm (23): Proven 7 (3.8), Putative 142 (76.3), Colonization 34 (18.3), Nonclassifiable 3 (1.6).
- Consensus definition (reference 57 in Appendix): Proven 7 (3.8), Probable 82 (44.1), Possible 19 (10.2), Nonclassifiable 78 (41.9).

Myologic evidence

- Culture**: 152 (81.7).
- Microscopy††: 3 (1.6).
- Histologic techniques‡‡: 7 (3.8).
- PCR§§: 43 (23.1).
- Galactomannan test¶¶: 113 (60.8).

*Some patients had ≥1 pathogen or form of mycologic evidence. BAL, bronchoalveolar lavage; EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycoses Study Group (21).
†A total of 2 patients had *A. fumigatus* and *A. niger* coinfection, 1 patient had *A. flavus* and *A. fumigatus* coinfection, 1 patient had *A. flavus* and *A. niger* coinfection, 1 patient had *A. fumigatus* and *A. terreus* coinfection, and 1 patient had *A. fumigatus* and *A. versicolor* coinfection.
‡One patient had an *Aspergillus* spp. infection diagnosed by culture. No species determination was provided. Other patient samples were diagnosed as Aspergillus spp, using serologic techniques.
§Small numbers of other pathogens were also retrieved from patient samples (Appendix Table 6, https://wwwnc.cdc.gov/EID/article/27/4/20-19895-App1.pdf).
¶AspICU method uses algorithm described by Blot et al. (23) for determining proven or putative aspergillosis in patients with influenza.
#Most (97.8%) patients were admitted to the ICU, mainly because of ARDS, need for mechanical ventilation, or both. We found that corticosteroid administration, chronic cardiovascular disease, renal failure, diabetes mellitus, and obesity were common characteristics among these patients. Approximately 1 in 5 patients had chronic pulmonary disease. Patients had many similarities to influenza-associated pulmonary aspergillosis (IAPA) patients from Schauwvlieghe et al. (22), including similar rates of mechanical ventilation (IAPA 90.0% vs. CAPA 94.1%), corticosteroid administration (IAPA 56.0% vs. CAPA 52.7%), baseline renal failure (IAPA 42.0% vs. CAPA 39.8%), obesity (IAPA 30.0% vs. CAPA 25.3%), and chronic pulmonary disease (IAPA 16.0% vs. CAPA 21.5%). IAPA patients had a higher proportion of malignancies (30.0% vs. 11.3%) and solid organ transplantation (13.0% vs. 2.7%); however, CAPA patients had a higher prevalence of diabetes mellitus (12.0% vs. 34.4%). In our study, 50.5% of patients had chronic cardiovascular disease. These differences in the distribution of baseline characteristics between IAPA and CAPA patients reflects the epidemiology of COVID-19, which is more common among those with chronic cardiovascular disease, whereas hematologic or oncologic malignancies (22) are more common among those with IAPA (reference 60 in Appendix). Only 2% of COVID-19 patients have cancer (reference 61 in Appendix).

Available guidelines for aspergillosis management recommend diagnostic procedures such as respiratory culture and galactomannan index of BAL samples (references 60,62 in Appendix). However, these procedures have a high risk for aerosolization; safety precautions should be used when handling samples from COVID-19 patients (references 63,64 in Appendix). The elevated risk for SARS-CoV-2 transmission and the initial recommendation against using bronchoscopy for COVID-19 diagnosis (references 63,64 in Appendix) might explain the low number of BAL tests used to diagnose CAPA in our study. Schauwvlieghe et al. (22) diagnosed IAPA by using BAL cultures in 63.0% of the patients and the galactomannan test in 88.0%. In the current study, BAL cultures tested positive for *Aspergillus* in 26.9% of COVID-19 patients; galactomannan tests were positive in 33.9% of patients. Alternative respiratory sample sources (e.g., bronchial aspirate, NBL, tracheal aspirate, and sputum) were used for cultures in 35.4% of IAPA patients (22) and 31.2% of CAPA patients. Alternative samples also were used for galactomannan tests in 17.2% of CAPA patients; if optical density index cutoff values were not standardized for alternative samples, clinicians used the values for BAL.
**Table 2.** Characteristics of 186 patients with coronavirus disease–associated pulmonary aspergillosis, March–August 2020*

| Patient characteristic                                      | No. (%)          |
|-------------------------------------------------------------|------------------|
| **Sex**                                                     |                  |
| F                                                          | 51 (27.4)        |
| M                                                          | 135 (72.6)       |
| **Median age, y (IQR)**                                     | 68 (58–73)       |
| **COVID-19†**                                               | 186 (100.0)      |
| **Median length of treatment, d (IQR)**                     | 7 (6–11)         |
| **Median time from COVID-19 diagnosis to CAPA, d (IQR)**    | 10 (5–16)        |
| **Intensive care unit stay**                                | 182 (97.8)       |
| **Median length of stay before CAPA diagnosis, d (IQR)**    | 8 (3–14)         |
| **Acute respiratory distress syndrome**                     | 180 (96.8)       |
| **Mechanical ventilation**                                  | 175 (94.1)       |
| **Median time on ventilation before CAPA diagnosis, d (IQR)** | 7 (3–13)         |
| **Corticosteroid use**                                      | 98 (52.7)        |
| **Concurrent conditions**                                   |                  |
| Chronic cardiovascular disease                              | 94 (50.5)        |
| Renal failure‡                                              | 74 (39.8)        |
| Diabetes mellitus                                          | 64 (34.4)        |
| Obesity                                                    | 47 (25.3)        |
| Chronic pulmonary disease                                   | 40 (21.5)        |
| Hematologic or oncologic disease§                           | 21 (11.3)        |
| Hematologic malignancy                                      | 10 (5.4)         |
| Solid tumor                                                 | 9 (4.8)          |
| Hematologic disease                                         | 2 (1.1)          |
| Solid organ transplantation¶                                | 4 (2.2)          |
| Neutropenia                                                 | 2 (1.1)          |
| **Other baseline conditions and characteristics#**          |                  |
| Lung infection                                              | 186 (100.0)      |
| Image abnormalities of the lungs                            | 182 (97.8)       |
| Computed tomography scan                                    | 134 (72.0)       |
| Radiograph                                                  | 88 (47.3)        |
| **Antifungal treatment**                                    |                  |
| **Median length of treatment, d (IQR)**                     | 16 (10–33)       |
| Amphotericin B                                              | 36 (19.4)        |
| Liposomal                                                   | 23 (12.4)        |
| Deoxycholate                                                | 11 (5.9)         |
| Lipid complex                                               | 2 (1.1)          |
| Echinocandins                                               | 24 (12.9)        |
| Anidulafungin                                               | 10 (5.4)         |
| Caspofungin                                                 | 13 (7.0)         |
| Micafungin                                                  | 1 (0.5)          |
| Ibrexafungerp                                               | 1 (0.5)          |
| Triazoles                                                   | 117 (62.9)       |
| Voriconazole                                                | 98 (52.7)        |
| Isavuconazole                                               | 23 (12.4)        |
| Posaconazole                                                | 4 (2.2)          |
| Fluconazole                                                 | 1 (0.5)          |
| **Overall mortality**                                       |                  |
| <6 wks                                                     | 89 (47.8)        |
| ≤12 wks                                                     | 93 (50.0)        |
| **Median time to death, d (IQR)**                           | 9 (3–18)         |
| **Cause of death**                                          |                  |
| CAPA                                                       | 32 (17.2)        |
| COVID-19                                                    | 51 (27.4)        |
| Other                                                       | 36 (19.4)        |
| **Median length of observation from CAPA diagnosis, d (IQR)** | 22 (7–42)        |

*Values are no. (%), except as indicated. Some patients had >1 baseline condition or characteristic, image abnormality, or antifungal drug. CAPA, COVID-19–associated pulmonary aspergillosis; COVID-19, coronavirus disease.†By definition, all CAPA patients had COVID-19 (Appendix Table 3, https://wwwnc.cdc.gov/EID/article/27/4/20-4895-App1.pdf).‡In total, 9 patients had hematologic malignancy; 3 had chronic leukemia, 3 had lymphoma, 2 had myelodysplastic syndrome, and 1 had acute leukemia. Eight patients had a solid tumor: 1 had breast cancer, 1 had carcinoma, 1 had cervical/uterine cancer, 1 had lung cancer, 1 had esophageal carcinoma, 1 had prostate cancer, 1 had testicular cancer, and 1 had urothelial carcinoma. Two patients had hematologic disease: 1 had acquired hemophilia type A and 1 had hemophagocytic lymphohistiocytosis.¶In total, 3 patients had a kidney transplant, 1 had a liver transplant, and 1 had a lung transplant. Small numbers of patients had other concurrent conditions and characteristics (Appendix Table 7).**In total, 32 patients died of CAPA or CAPA/COVID-19: 7 died of CAPA only; 25 died of CAPA and COVID-19. In addition, 26 died of COVID-19 only.
Almost all (97.8%) patients had imaging abnormalities; however, many had only marginally typical features of aspergillosis, hampering the differential diagnosis of CAPA according to radiologic criteria.

Positive isolates were recovered from 81.1% of CAPA patients. Similar to IAPA patients, the most common (80.3%) pathogen was *A. fumigatus* (22). In total, 5 patients had azole-resistant infections: 4 *A. fumigatus* and 1 *A. lentulus* infection. We noted 2 patients who had a possible previous exposure to triazoles. The professions of these 2 patients involved exposure to fungicides and manipulated organic matter containing triazole-resistant *A. fumigatus*. Therefore, the treating teams hypothesized that workplace exposure might have contributed to these patients’ illness. We found a similar proportion of patients with previous azole exposure as Verweij et al. (reference 65 in Appendix); however, the proportion found by Verweij et al. should be considered with caution because of small sample size.

Triazoles, especially voriconazole, were the most frequently administered antifungal drugs: 52.7% of the study cohort and 71.5% of the patients on antifungal treatment received voriconazole. We found that voriconazole use was associated with decreased death. The first-line use of voriconazole in 79 (80.6%) of 98 patients aligns with current recommendations (references 56,60,62 in Appendix).

We found a 50% mortality rate at 12 weeks after CAPA diagnosis. This finding is similar to the 51.0% mortality rate of IAPA patients in the same timeframe; however, these rates are almost 20 points higher than in other cohorts, such as aspergillosis patients with acute leukemia (33.8%) (reference 66 in Appendix). Nonetheless, in our study CAPA was attributed as the main reason for death in only 17.2% of the patients, whereas in Koehler et al. (reference 66 in Appendix), it was the main cause of death for 26.9% of patients with hematologic conditions.

We found an overall 6.9% cumulative incidence for CAPA among patients during the study period, although incidences varied by institution (1.0%–39.1% of CAPA patients admitted to ICU). In most facilities, the rates of CAPA were lower than those of IAPA (14%–19%) (reference 67 in Appendix). However, these ranges might vary according to diagnostic protocols in the different countries and healthcare facilities. Differences in screening practices for CAPA in COVID-19 patients might have affected detection rates and therefore our calculations of cumulative incidence (8). Further analyses are necessary to establish the geographic variance of this rate.

The first limitation of this study is that, because of the cross-sectional design of this study, we could not control for disease severity. Second, samples from the lower respiratory tract are the best way to differentiate between colonization and infection, but a low percentage of patients in this study had mycologic evidence from BAL culture or galactomannan tests. Third, we analyzed many cases from literature and could not contact certain authors for further details. In addition, institutions might not have documented all CAPA cases in the literature or FungiScope registry. Given the regional variability of the patient distribution,
longitudinal studies might be a more appropriate tool to determine rates. Finally, because of the retrospective nature of the study, we could not retrieve the necessary clinical and diagnostic details of all patients. As a result, many patients were not classifiable according to the definitions used in this article, possibly contributing to an underdiagnosis of CAPA.

In conclusion, we described a large cohort of CAPA patients using cases from the literature and the FungiScope registry. CAPA occurs mostly in ICU patients on mechanical ventilation. We found that CAPA patients had high rates of chronic cardiovascular disease, renal failure, diabetes mellitus, and corticosteroid use. We also found that CAPA substantially contributed to a high death rate in COVID-19 patients, although cumulative incidence varied by treatment site. We believe that improved screening can identify and enable early treatment of CAPA.

Members of the FungiScope European Confederation of Medical Mycology/the International Society for Human and Animal Mycology Working Group include Pilar Escribano, Mariana Chumbita, Martha Avilés-Robles, Julia Lanznaster, Mario Fernández-Ruiz, Guillaume Desoubeaux, Stefan Kluge, Matthias Kochanek, Norma B. Fernández, P. Lewis White, Kauser Jabeen, Florian Reizine, Stefaan van Biesen, Alexandre Alario, Théo Ghelfenstein-Ferreira, Lynn Rutsaert, Jens T. van Praet, Emmanouil Glapedakis, Tobias Lahmer, Ali S. Omrani, Alida Fe Talento, Giuseppe Bruno, Andreas van Arkel, and Robbert Bentvelsen.

This work was carried out as part of routine duties. FungiScope is supported by unrestricted grants from Amplyx Pharmaceuticals, Inc.; Basilea Pharmaceuticals; Cidara Therapeutics, Inc.; F2G Ltd.; Matinas BioPharma; Mundipharma International; Pfizer Inc.; and Scynexis, Inc. FungiScope has been supported in the past by unrestricted grants from Astellas Pharma Inc., Gilead Sciences Inc., and MSD Sharp & Dohme GmbH.

J.S. has received research grants from Basilea Pharmaceuticals International Ltd. and travel grants from the Meta-Alexander Foundation and German Society for Infectious Diseases, outside the context of the submitted work. C.G.V. has received grants and speaker fees from Gilead Sciences, Inc. and Merck Sharp & Dohme Corp., and speaker fees from Janssen Pharmaceuticals, Lilly, Novartis, and Pfizer Inc., outside the context of the submitted work. M.S. receives funding from the Medical Faculty of the University of Hamburg, Hamburg, Germany for clinical leave. F.H. received research and other honoraria from Correvio Pharma Corp., InfectoPharm Arzneimittel und Consilium GmbH, and Novartis, outside the context of the submitted work. K.F.P. is financially supported by the Coordination for the Improvement of Higher Education Personnel Foundation and Ministry of Education of Brazil (proposal no. 09/2020) and a nonfinancial scientific grant from IMMY, outside the context of the submitted work. D.R.G. received honoraria from Stepstone Pharma GmbH and unconditional grants from MSD Italia Srl and Correvio Pharma Corp. J.F.M. reports grants from F2G Ltd. and Pulmocide, consultancy fees from Scynexis, Inc., and speaker fees from Gilead Sciences Inc., United Medical, and Teva Pharmaceutical Industries Ltd., outside the context of the submitted work. J.P.G. has participated in advisory boards and received speaker honoraria from Pfizer Inc. and Gilead Sciences Inc., outside the context of the submitted work. E.S. has received grants from the Philipp Schwartz Initiative of the Alexander von Humboldt Foundation. O.A.C. is financially supported by the German Federal Ministry of Research and Education; is funded by the Deutsche Forschungsgemeinschaft under Germany’s Excellence Strategy (CECAD, EXC 2030 – 390661388); has received research grants from Actelion Pharmaceuticals Global, Amplyx Pharmaceuticals, Inc., Astellas Pharma Inc., Basilea Pharmaceuticals International Ltd., Cidara Therapeutics, Inc., Da Volterra, F2G Ltd., Gilead Sciences Inc., Janssen Pharmaceuticals, The Medicines Company, Melinta Therapeutics, Merck Sharp & Dohme Corp., Octapharma AG, Pfizer Inc., and Scynexis, Inc.; is a consultant to Actelion Pharmaceuticals Global, Allecr Therapeutics GmbH, Amplyx Pharmaceuticals, Inc., Astellas Pharma Inc., Basilea Pharmaceutical International Ltd., BIOSYS USA LLC, Cidara Therapeutics, Inc., Da Volterra, Entasis Therapeutics, F2G Ltd., Gilead Sciences Inc., Matinas BioPharma Holdings, Inc., MedPace, Inc., The Menarini Group, Merck Sharp & Dohme Corp., Mylan Inc., Nabstra Therapeutics plc, NOXXON Pharma, Octapharma AG, Paratek Pharmaceuticals, Inc., Pfizer Inc., Pharmaceutical Solutions Industry, Roche Diagnostics, Scynexis, Inc., and Shionogi Inc.; and received lecture honoraria from Al-Jazeera Pharmaceutical Industries, Astellas Pharma Inc., Basilea Pharmaceutica International Ltd., Gilead Sciences Inc., Grupo Biotoscana, Merck Sharp & Dohme Corp., and Pfizer Inc., outside the context of the submitted work. P.K. has received nonfinancial scientific grants from Miltenyi Biotec GmbH and the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, and lecture honoraria from or is advisor to Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma Inc., European Confederation of Medical Mycology, Gilead Sciences Inc., Gesundheits und Pflegezentrum Rüsselsheim gemeinnützige GmbH, Merck Sharp & Dohme Corp., and University Hospital, Ludwig Maximilian University of Munich, and is advisor to Gilead Sciences Inc. and NOXXON N.V. outside the context of the submitted work.
COVID-19–Associated Pulmonary Aspergillosis

About the Author
Dr. Salmanton-García is an epidemiologist at University Hospital Cologne, Cologne. His primary research interests are invasive fungal infections, infectious diseases, epidemiology, and database management.

References

1. World Health Organization. Pneumonia of unknown cause. 2020 [cited 2021 Jun 23]. https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/.
2. Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. BMJ. 2020;368:m1036. https://doi.org/10.1136/bmj.m1036
3. Koehler P, Meis JF, Ostrosky-Zeichner L, Böll B, Hoeingl M, Cornely OA. COVID-19–associated pulmonary aspergillosis—management. 2020 [cited 2020 May 30]. https://repository.publisso.de/resource/frl%3A6421494.
4. Beer KD, Jackson BR, Chiller T, Verweij PE, Van de Veerdronk FL, Wauters J. Does pulmonary aspergillosis complicate coronavirus disease 2019? Crit Care Explor. 2020;2:e0211. https://doi.org/10.1097/CCE.0000000000000211
5. Costantini C, van de Veerdronk FL, Romani L. COVID-19–associated pulmonary aspergillosis: the other side of the coin. Vaccines (Basel). 2020;8:713. https://doi.org/10.3390/vaccines8040713
6. Arastehfar A, Carvalho A, van de Veerdronk FL, Jenks JD, Koehler P, Krause R, et al. COVID-19 associated pulmonary aspergillosis (CAPA)—from immunology to treatment. J Fungi (Basel). 2020;6:91. https://doi.org/10.3390/jof6020091
7. Alano J, Delièrre S, Foddil S, Bretagne S, Megarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020;8:e48–9. https://doi.org/10.1016/S2213-2600(20)30237-X
8. Koehler P, Cornely OA, Bottiger BW, Dusse F, Eichnauer DA, Fuchs F, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63:528–34. https://doi.org/10.1111/myc.13096
9. Dellièrre S, Dudoignon E, Foddil S, Voicu S, Collet M, Ollic PA, et al. Risk factors associated with COVID-19 associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort. Clin Microbiol Infect. 2020. https://doi.org/10.1016/j.cmi.2020.12.005
10. Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients. Emerg Infect Dis. 2020;26:2694-6. https://doi.org/10.3201/eid2611.2003504
11. Chang CC, Seninning R, Kim J, Goyal R. An acute pulmonary coccidioidomycosis coinfection in a patient presenting with multifocal pneumonia with COVID-19. J Investig Med High Impact Case Rep. 2020;8:2324709620972244. https://doi.org/10.217322/2324709620972244
12. Poignon C, Blaize M, Vezinet C, Lampros A, Monsel A, Fekkar A. Invasive pulmonary fusariosis in an immunocompetent critically ill patient with severe COVID-19. Clin Microbiol Infect. 2020;26:1582-4. https://doi.org/10.1016/j.cmi.2020.06.026
13. Messina FA, Marin E, Cáceres DH, Romero M, Depardo R, Priarone MM, et al. Coronavirus disease 2019 (COVID-19) in a patient with disseminated histoplasmosis and HIV—a case report from Argentina and literature review. J Fungi (Basel). 2020;6:275. https://doi.org/10.3390/jof6040275
14. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2020. https://doi.org/10.1016/j.ajem.2020.09.032
15. Menon AA, Berg DD, Brea EJ, Deutsch AJ, Kidia KK, Thurber EG, et al. A case of COVID-19 and Pneumocystis jiroveci coinfection. Am J Respir Crit Care Med. 2020;202:136–8. https://doi.org/10.1164/rccm.202003-0766LE
16. Ventoulis I, Sarmouli T, Amoiridou P, Mantzara P, Exidari M, Gioula G, et al. Bloodstream infection by Saccharomyces cerevisiae in two COVID-19 patients after receiving supplementation of Saccharomyces in the ICU. J Fungi (Basel). 2020;6:698. https://doi.org/10.3390/jof6030098
17. van Arkel ALE, Rijpstra TA, Beldersos HNA, Van Wijngaarden P, Verweij PE, Bentvelsen RG. COVID-19-associated pulmonary aspergillosis. Am J Respir Crit Care Med. 2020;202:132–5. https://doi.org/10.1164/rccm.202004-1038LE
18. Zhang SY, Lian JS, Hu JH, Zhang XL, Lu YF, Cai H, et al. Clinical characteristics of different subtypes and risk factors for the severity of illness in patients with COVID-19 in Zhejiang, China. Infect Dis Poverty. 2020;9:85. https://doi.org/10.1186/s40249-020-00710-6
19. Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19–associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan. Mycoses. 2020;63:766–70. https://doi.org/10.1111/myc.13135
20. Lamothe F, Glampedakis E, Boillat-Blanco N, Oddo M, Pagani JL. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. Clin Microbiol Infect. 2020;26:1706–8. https://doi.org/10.1016/j.cmi.2020.07.010
21. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley J, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71:1367–76. https://doi.org/10.1093/cid/ciz1008
22. Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke M, Van Tienen C, et al.; Dutch-Belgian Mycosis Study Group. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6:782–92. https://doi.org/10.1016/S2213-2600(18)30274-1
23. Blot SI, Taacone FS, Van den Abeele AM, Bulpa P, Meersseman W, Brusselsaers N, et al.; AspICU Study Investigators. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186:56–64. https://doi.org/10.1164/rccm.201111-1978OC
24. Koehler P, Bassetti M, Kochanek M, Shimabukuro-Vornhagen A, Cornely OA. Intensive care management of influenza-associated pulmonary aspergillosis. Clin Microbiol Infect. 2019;25:1501–9. https://doi.org/10.1016/j.cmi.2019.04.031
25. Verweij PE, Rijnders BJA, Brüggemann RM, Azoulay E, Bassetti M, Blot S, et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med. 2020;46:1524–35. https://doi.org/10.1007/s00134-020-06091-6
26. Fernández NB, Cáceres DH, Beer KD, Irrazabal C, Delgado G, Farias L, et al. Ventilator-associated pneumonia
involving *Aspergillus flavus* in a patient with coronavirus disease 2019 (COVID-19) from Argentina. Med Mycol Case Rep. 2020 Jul 5 [Epub ahead of print]. https://doi.org/10.1016/j.mycr.2020.07.001

27. Sharma A, Hofmeyr A, Bansal A, Thakkar D, Lam L, Harrington Z, et al. COVID-19-associated pulmonary aspergillosis (CAPA): An Australian case report. Med Mycol Case Rep. 2020 Jun 18 [Epub ahead of print]. https://doi.org/10.1016/j.mycr.2020.06.002

28. Prattes J, Valentin T, Hoenigl M, Talakic E, Reisinger AC, Eller P. Invasive pulmonary aspergillosis complicating COVID-19 in the ICU - A case report. Med Mycol Case Rep. 2020 May 11 [Epub ahead of print]. https://doi.org/10.1016/j.mycr.2020.05.001

29. Rutsaert L, Steinfort N, Van Hunselt T, Bomans P, Naesens R, Mertes H, et al. COVID-19-associated invasive pulmonary aspergillosis. Ann Intensive Care. 2020;10:71. https://doi.org/10.1186/s13613-020-00686-4

30. Sarrazyn C, Dhaese S, Demey B, Vandecasteele S, Reyniers M, Van Praet JT. Incidence, risk factors, timing and outcome of influenza versus Covid-19 associated putative invasive aspergillosis. Infect Control Hosp Epidemiol. 2020 Sep;59:1-7 [Epub ahead of print]. https://doi.org/10.1017/ice.2020.460

31. Lemos DRQ, D’Angelo SM, Farias LABG, Almeida MM, Gomes RG, Pinto GP, et al. Health system collapse 45 days after the detection of COVID-19 in Ceará, Northeast Brazil: a preliminary analysis. Rev Soc Bras Med Trop. 2020;53:e20200354. https://doi.org/10.1590/0037-8682-0354-2020

32. Helleberg M, Steensen M, Arendrup MC. Invasive aspergillosis in patients with severe COVID-19 pneumonia. Clin Microbiol Infect. 2021;27:147–8. https://doi.org/10.1016/j.cmi.2020.07.047

33. Alainio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020;8:e48–9. https://doi.org/10.1016/S2213-2600(20)30237-X

34. Bharat S, D’Souza F, Ali Z, Vyas P, Agarwal S, Agarwal R, et al. COVID-19 associated pulmonary aspergillosis: adding insult to injury. Lancet Microbe. 2020;1:e106. https://doi.org/10.1016/j.lsmicro.2020.03.006-X

35. Meijer EJ, Dofferhoff ASM, Hoiting O, Buil JB, Meis JF. Azole-resistant COVID-19–associated pulmonary aspergillosis in an immunocompetent host: a case report. J Fungi (Basel). 2020;6:79. https://doi.org/10.3390/jof6020079

36. van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG. COVID-19-associated pulmonary aspergillosis. Am J Respir Crit Care Med. 2020;202:132–5. https://doi.org/10.1164/rccm.202004-1038LE

37. Van Biesen S, Kwa D, Bosman RJ, Juffermans NP. Detection of invasive pulmonary aspergillosis in COVID-19 with non-directed BAL. Am J Respir Crit Care Med. 2020;202:1171–3. https://doi.org/10.1164/rccm.202005-2018LE

38. Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19–associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan. Mycoses. 2020;63:766–70. https://doi.org/10.1111/myc.13135

39. Schein F, Muñoz-Pons H, Mahinc C, Grange R, Cathébras P, Flori P. Fatal aspergillosis complicating severe SARS-CoV-2 infection: a case report. J Mycol Med. 2020;30:101039. https://doi.org/10.1016/j.jymcm.2020.101039

40. Lahmer T, Rosch S, Spinner C, Geisler F, Schmid RM, Huber W. Invasive pulmonary aspergillosis in severe coronavirus disease 2019 pneumonia. Clin Microbiol Infect. 2020;26:1428–9. https://doi.org/10.1016/j.cmi.2020.05.032

41. Mohamed A, Hassan T, Trzoz-Grzybowska M, Thomas J, Quinn A, O’Sullivan M, et al. Multi-triazole-resistant *Aspergillus fumigatus* and SARS-CoV-2 co-infection: a lethal combination. Med Mycol Case Rep. 2020 Jun 26 [Epub ahead of print]. https://doi.org/10.1016/j.mycr.2020.06.005

42. Antinori S, Rech R, Galimberti L, Castelli A, Angeli E, Fossati T, et al. Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: a diagnostic challenge. Travel Med Infect Dis. 2020;38:101752. https://doi.org/10.1016/j.tmaid.2020.101752

43. Bartoletti M, Pascale R, Cricca M, Rinaldi M, Maccaro A, Bussini L, et al.; PREDICO Study Group. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. Clin Infect Dis. 2020 Jul 28 [Epub ahead of print]. https://doi.org/10.1093/cid/ciaa1065

44. Bruno G, Fabrizio C, Buccoliero GB. COVID-19–associated pulmonary aspergillosis: adding insult to injury. Lancet Microbe. 2020;1:e106. https://doi.org/10.1016/S2666-5247(20)30063-X

45. Abdalla S, Almaslamani MA, Hashim SM, Ibrahim AS, Omran AS. Fatal coronavirus disease 2019 pneumonia: a case report. IDCases. 2020;22:e00935. https://doi.org/10.1016/j.idcr.2020.e00935

46. van Arkel ALE, Ripstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG. COVID-19–associated pulmonary aspergillosis. Am J Respir Crit Care Med. 2020;202:132–5. https://doi.org/10.1164/rccm.202004-1038LE

47. Van Biesen S, Kwa D, Bosman RJ, Juffermans NP. Detection of invasive pulmonary aspergillosis in COVID-19 with non-directed BAL. Am J Respir Crit Care Med. 2020;202:1171–3. https://doi.org/10.1164/rccm.202005-2018LE

48. Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19–associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan. Mycoses. 2020;63:766–70. https://doi.org/10.1111/myc.13135

49. Abdalla S, Almaslamani MA, Hashim SM, Ibrahim AS, Omran AS. Fatal coronavirus disease 2019–associated pulmonary aspergillosis; a report of two cases and review of the literature. IDCases. 2020;22:e00935. https://doi.org/10.1016/j.idcr.2020.e00935

50. Falces-Romero I, Ruiz-Bastían M, Diaz-Pollán B, Maseda E, García-Rodríguez J; SARS-CoV-2 Working Group. Isolation of *Aspergillus* spp. in respiratory samples of patients with COVID-19 in a Spanish tertiary care hospital. Mycoses. 2020;63:1144–8. https://doi.org/10.1111/myc.13135

Address for correspondence: Jon Salmanton-García, University of Cologne, Herderstrasse 52-54, Cologne 50931, Germany; email: jon.salmanton-garcia@uk-koeln.de
Appendix

Additional References

51. Falces-Romero I, Ruiz-Bastián M, Díaz-Pollán B, Maseda E, García-Rodríguez J; SARS-CoV-2 Working Group. Isolation of Aspergillus spp. in respiratory samples of patients with COVID-19 in a Spanish tertiary care hospital. Mycoses. 2020;63:1144–8. PubMed https://doi.org/10.1111/myc.13155

52. Machado M, Valerio M, Álvarez-Uría A, Olmedo M, Veintimilla C, Padilla B, et al.; COVID-19 Study Group. Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity. Mycoses. 2021;64:132–43. PubMed https://doi.org/10.1111/myc.13213

53. Marr KA, Platt A, Tornheim JA, Zhang SX, Datta K, Cardozo C, et al. Aspergillosis complicating severe coronavirus disease. Emerg Infect Dis. 2021;27:18–25. PubMed https://doi.org/10.3201/eid2701.202896

54. Lamoth F, Glampedakis E, Boillat-Blanco N, Oddo M, Pagani JL. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. Clin Microbiol Infect. 2020;26:1706–8. PubMed https://doi.org/10.1016/j.cmi.2020.07.010

55. White PL, Dhillon R, Cordey A, Hughes H, Faggian F, Soni S, et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the intensive care unit. Clin Infect Dis. 2020;ciaa1298. PubMed https://doi.org/10.1093/cid/ciaa1298

56. Seidel D, Durán Graeff LA, Vehreschild MJGT, Wisplinghoff H, Ziegler M, Vehreschild JJ, et al.; FungiScope Group. FungiScope—global emerging fungal infection registry. Mycoses. 2017;60:508–16. PubMed https://doi.org/10.1111/myc.12631
57. Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al.; European Confederation of Medical Mycology; International Society for Human Animal Mycology; Asia Fungal Working Group; INFOCUS Latin American Clinical Mycology/International Society for Human and Animal Mycology Working Group; International Society for Human and Animal Mycology Pan Africa Mycology Working Group; European Society for Clinical Microbiology; Infectious Diseases Fungal Infection Study Group; ESCMID Study Group for Infections in Critically Ill Patients; Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy; Medical Mycology Society of Nigeria; Medical Mycology Society of China Medicine Education Association; Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology; Association of Medical Microbiology; Infectious Disease Canada. Defining and managing COVID-19–associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2020 Dec 14 [Epub ahead of print]. PubMed

58. European Society of Clinical Microbiology and Infectious Disease. Clinical breakpoints for fungi (Candida and Aspergillus species). 2021 [cited 2020 Jun 1]. https://www.eucast.org/astoffungi/clinicalbreakpointsforantifungals

59. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing of filamentous fungi. 2017 [cited 2020 Jun 2]. https://clsi.org/media/1896/m61ed1_sample.pdf

60. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11:6317. PubMed https://doi.org/10.1038/s41467-020-19741-6

61. Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24:e1–38. PubMed https://doi.org/10.1016/j.cmi.2018.01.002

62. Desai A, Sachdeva S, Parekh T, Desai R. COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob Oncol. 2020;6:557–9. PubMed https://doi.org/10.1200/GO.20.00097

63. Patterson TF, Thompson GR III, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1–60. PubMed https://doi.org/10.1093/cid/ciw326
64. Wahidi MM, Lamb C, Murgu S, Musani A, Shojaee S, Sachdeva A, et al. American Association for Bronchology and Interventional Pulmonology (AABIP) statement on the use of bronchoscopy and respiratory specimen collection in patients with suspected or confirmed COVID-19 infection. J Bronchology Interv Pulmonol. 2020;27:e52–4. PubMed
https://doi.org/10.1097/LBR.0000000000000681

65. Koehler P, Cornely OA, Kochanek M. Bronchoscopy safety precautions for diagnosing COVID-19 associated pulmonary aspergillosis—a simulation study. Mycoses. 2020;64:55–9. PubMed

66. Verweij PE, Ananda-Rajah M, Andes D, Arendrup MC, Brüggemann RJ, Chowdhary A, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat. 2015;21–22:30–40. PubMed
https://doi.org/10.1016/j.drup.2015.08.001

67. Koehler P, Hamprecht A, Bader O, Bekeredjian-Ding I, Buchheidt D, Doelken G, et al. Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. Int J Antimicrob Agents. 2017;49:218–23. PubMed
https://doi.org/10.1016/j.ijantimicag.2016.10.019

68. Vanderbeke L, Spriet I, Breynaert C, Rijnders BJA, Verweij PE, Wouters J. Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment. Curr Opin Infect Dis. 2018;31:471–80. PubMed https://doi.org/10.1097/QCO.0000000000000504
Appendix Table 1. Data sources describing patients with coronavirus disease–associated pulmonary aspergillosis, March–August 2020

| Location and reference |
|------------------------|
| Argentina              |
| N.B. Fernández, et al. (26) |
| Australia              |
| A. Sharma, et al. (27)  |
| Austria                |
| J. Prattes, et al. (28) |
| Belgium                |
| L. Rutsaert, et al. (29) |
| C. Sarrazyn, et al. (30) |
| Brazil                 |
| D.R.Q. Lemos, et al. (31) |
| Denmark                |
| M. Helleberg, et al. (32) |
| France                 |
| A. Alanio, et al. (33)  |
| M. Blaise, et al. (34)  |
| D. Dupont, et al. (35)* |
| J.P. Gangneux, et al. (36) |
| T. Gheffenstein-Ferreira, et al. (37) |
| F.X. Lescure, et al. (38) |
| F. Schein, et al. (39)† |
| Germany                |
| P. Koehler, et al. (40) |
| T. Lahmer, et al. (41)  |
| Ireland                |
| A. Mohamed, et al. (42) |
| Italy                  |
| S. Antinori S, et al. (43) |
| M. Bartoletti, et al. (44) |
| G. Bruno, et al. (45)  |
| Netherlands            |
| E.F.J. Meijer, et al. (46) |
| A.L.E. van Arkel, et al. (47) |
| S. Van Biesen, et al. (48) |
| Pakistan               |
| N. Nasir, et al. (49)   |
| Qatar                  |
| S. Abdalla, et al. (50) |
| Spain                  |
| I. Falces-Romero I, et al. (Appendix Reference 51)† |
| M. Machado, et al. (Appendix Reference 52)* |
| K.A. Marr KA, et al. (Appendix Reference 53)*‡ |
| Switzerland            |
| F. Lamoth, et al. (Appendix Reference 54) |
| United Kingdom         |
| P.L. White, et al. (Appendix Reference 55) |

*The patients described in references 35, Appendix Reference 52, and Appendix Reference 53 were also documented in the FungiScope registry during the preparation of the current work.
†References 39 and Appendix Reference 51 describe patients that were not previously admitted to intensive care units.
‡Appendix Reference 53 includes cases from the United States.
**Appendix Table 2.** Data collection tool used in study on CAPA, March–August 2020*

| Case published in the literature? (If yes, please provide the DOI number): |
| Sex: |
| Age: |
| Country: |
| Year of infection: |
| Baseline conditions: |
| COVID-19: |
| - Length of treatment, *in days*: |
| - Treatment sequence: |
| ICU stay, *(yes/no)*: |
| - Length from ICU admission to CAPA, *in days*: |
| - ARDS, *(yes/no)*: |
| - Mechanical ventilation, *(yes/no)*: |
| - Start of ventilation before CAPA, *in days*: |
| Other relevant underlying conditions, *(please provide details)*: |
| Diagnostics: |
| Microbiological evidence: |
| - Tests: |
| - Culture, *origin*: |
| - Microscopy, *origin*: |
| - Histology, *origin*: |
| - PCR, *origin*: |
| - Galactomannan, *origin and ODI*: |
| - Pathogen: |
| - Coinfection *(bacterial, fungal, viral)*: |
| Image abnormalities, *(yes/no)*: |
| - CT scan, *(please provide details)*: |
| - x-ray, *(please provide details)*: |
| Site(s) of CAPA involvement: |
| Antifungal susceptibility test: |
| Method: |
| MIC value per antifungal: |
| Antifungal treatment: |
| Length of treatment, *in days*: |
| Treatment sequence: |
| Outcome *(alive/dead)*: |
| Observation days from CAPA diagnosis, *in days*: |
| Day of death: |
| Autopsy, *(yes/no)*: |
| Death attributable to, *(please provide details)*: |

*ARDS, acute respiratory distress syndrome; CAPA, COVID-19–associated pulmonary aspergillosis; COVID-19, coronavirus disease; CT, computed tomography scan; DOI, digital object identifier; ICU, intensive care unit; MIC, minimum inhibitory concentration; ODI, optical density index.
### Appendix Table 3. Coronavirus disease treatment in patients with aspergillosis, March–August 2020

| Treatment                                          | No. (%) |
|----------------------------------------------------|---------|
| Hydroxy-chloroquine                                 | 110 (59.1) |
| Hydroxychloroquine                                  | 98 (52.7) |
| Chloroquine                                         | 12 (6.5) |
| **Antiviral treatment**                             |         |
| Lopinavir/ritonavir                                  | 56 (30.1) |
| Remdesivir                                          | 3 (1.6) |
| Lopinavir/ritonavir + remdesivir                    | 2 (1.1) |
| Atazanavir                                          | 1 (0.5) |
| Darunavir + cobicistat                               | 1 (0.5) |
| Lopinavir/ritonavir + darunavir                      | 1 (0.5) |
| Lopinavir/ritonavir + oseltamivir                   | 1 (0.5) |
| Lopinavir/ritonavir + ribavir                       | 1 (0.5) |
| Oseltamivir                                         | 1 (0.5) |
| **Corticosteroids**                                 |         |
| Methylprednisolone                                  | 27 (14.5) |
| Hydrocortisone                                      | 9 (4.8) |
| Dexamethasone                                       | 9 (4.8) |
| Hydrocortisone + methylprednisolone                 | 4 (2.2) |
| Dexamethasone + hydrocortisone + methylprednisolone | 1 (0.5) |
| Dexamethasone + hydrocortisone + prednisolone       | 1 (0.5) |
| Dexamethasone + methylprednisolone                  | 1 (0.5) |
| Methotrexate                                        | 1 (0.5) |
| Methylprednisolone + prednisone                     | 1 (0.5) |
| Prednisolone                                        | 1 (0.5) |
| Prednisone                                          | 1 (0.5) |
| Nonspecified corticosteroids                         | 13 (7.0) |
| Tocilizumab                                         | 51 (27.4) |
| **Total**                                           | 134 (72.0) |

### Appendix Table 4. Minimum inhibitory concentration values for *Aspergillus fumigatus* from 32 patients with coronavirus disease, March–August 2020

| Antimicrobial drug, no. samples* | Antifungal susceptibility testing, no. (IQR)† |
|---------------------------------|-----------------------------------------------|
|                                 | EUCAST | CLSI | E-test |
|                                 | n = 20 | n = 1 | n = 11 |
| Amphotericin B, 30              | 0.25 (0.25–0.5) | 0.5 (0.5–0.5) | 0.25 (0.125–0.38) |
| Anidulafungin, 5                | 0.008 (0.008–0.008) | 0.008 (0.008–0.008) | 0.125 (0.125–0.25) |
| Caspofungin, 10                 | 0.125 (0.125–0.125) | 0.125 (0.125–0.25) | 0.008 (0.008–0.008) |
| Micafungin, 1                   | 1      | 0.008 (0.008–0.008) | 0.06 (0.03–0.125) |
| Isavuconazole, 22               | 0.5 (0.5–1) | 16 (16–16) | 0.38 (0.25–0.38) |
| Itraconazole, 25                | 0.5 (0.25–0.5) | 0.5 (0.5–0.5) | 0.125 (0.06–0.25) |
| Posaconazole, 24                | 0.064 (0.032–0.064) | 0.5 (0.5–0.5) | 0.125 (0.094–0.125) |
| Voriconazole, 31                | 0.5 (0.125–0.5) | 2 (2–2) | 0.094 (0.094–0.125) |

*No. samples tested for susceptibility to each antifungal drug. One sample per patient.
†CLSI, Clinical and Laboratory Standards Institute (Reference 59 in Appendix); EUCAST, European Committee on Antimicrobial Susceptibility Testing (Reference 58 in Appendix).
### Appendix Table 5. Antifungal treatments for aspergillosis in patients with coronavirus disease, March–August 2020

| Treatment | no. (%) |
|-----------|---------|
| VRZ | 65 (34.9) |
| Isavuconazole | 9 (4.8) |
| Liposomal AMB | 8 (4.3) |
| VRZ + AMB + nebulized AMB, VRZ | 7 (3.8) |
| Caspofungin | 5 (2.7) |
| VRZ, isavuconazole | 4 (2.2) |
| Posaconazole | 3 (1.6) |
| VRZ, liposomal AMB | 3 (0.6) |
| Anidulafungin | 2 (1.1) |
| Caspofungin + VRZ, VRZ | 2 (1.1) |
| Caspofungin, VRZ | 2 (1.1) |
| Deoxycholate AMB | 2 (1.1) |
| VRZ + AMB + nebulized AMB | 2 (1.1) |
| Anidulafungin, anidulafungin + liposomal AMB, liposomal AMB | 1 (0.5) |
| Anidulafungin, anidulafungin + liposomal AMB, liposomal AMB, anidulafungin + isavuconazole | 1 (0.5) |
| Caspofungin + VRZ, VRZ, liposomal AMB | 1 (0.5) |
| Caspofungin, isavuconazole | 1 (0.5) |
| FLZ, VRZ | 1 (0.5) |
| Isavuconazole + anidulafungin, anidulafungin | 1 (0.5) |
| Isavuconazole + anidulafungin, isavuconazole | 1 (0.5) |
| Isavuconazole, isavuconazole + nebulized AMB | 1 (0.5) |
| isavuconazole, AMB lipid complex | 1 (0.5) |
| liposomal AMB + anidulafungin | 1 (0.5) |
| liposomal AMB, isavuconazole | 1 (0.5) |
| liposomal AMB, isavuconazole, liposomal AMB | 1 (0.5) |
| liposomal AMB, VRZ | 1 (0.5) |
| liposomal AMB, VRZ, VRZ + caspofungin | 1 (0.5) |
| AMB lipid complex | 1 (0.5) |
| Micafungin, VRZ, isavuconazole, liposomal AMB | 1 (0.5) |
| VRZ + anidulafungin | 1 (0.5) |
| VRZ, ibrexafungerp* | 1 (0.5) |
| VRZ, liposomal AMB + anidulafungin | 1 (0.5) |
| VRZ, liposomal AMB, isavuconazole | 1 (0.5) |
| VRZ, posaconazole | 1 (0.5) |
| VRZ, VRZ + anidulafungin, liposomal AMB + anidulafungin | 1 (0.5) |
| VRZ, VRZ + caspofungin, VRZ | 1 (0.5) |
| No antifungal treatment | 49 (26.3) |
| Total | 186 (100.0) |

*Patient enrolled in the FURI Study (NCT 03059992; EuDra-CT 2017–000381–29). AMB, amphotericin B; FLZ, fluconazole; VRZ, voriconazole. + indicates drugs used in combination.
| Sample                                      | Pathogens                                                                 | no. (%) |
|---------------------------------------------|---------------------------------------------------------------------------|---------|
| Blood                                      | *Clostridium perfringens*                                                  | 1 (0.5) |
|                                             | Coagulase-negative Staphylococci                                          | 1 (0.5) |
|                                             | *Enterococcus* spp.                                                       | 1 (0.5) |
|                                             | *Enterococcus faecium*                                                    | 1 (0.5) |
|                                             | *Pseudomonas aeruginosa*                                                  | 2 (1.1) |
|                                             | *Staphylococcus aureus*                                                  | 1 (0.5) |
|                                             | *Staphylococcus epidermidis*                                              | 1 (0.5) |
|                                             | *Staphylococcus epidermidis, Staphylococcus haemolyticus*                 | 1 (0.5) |
|                                             | *Stenotrophomonas maltophilia*                                            | 1 (0.5) |
|                                             | Unknown bacteria                                                          | 1 (0.5) |
| Blood + catheter tip                       | Coagulase-negative Staphylococci, blood; *Klebsiella pneumoniae*, catheter tip | 1 (0.5) |
| Blood + lung                               | *Enterobacter cloacae*, blood; *Pseudomonas aeruginosa*, NBL              | 1 (0.5) |
|                                             | *Enterococcus faecalis*, blood and tracheal aspirate; *Staphylococcus capitis*, blood | 1 (0.5) |
|                                             | *Enterococcus* spp., blood; *Serratia* spp., NBL                         | 1 (0.5) |
|                                             | *Pseudomonas aeruginosa*, bronchial aspirate                              | 1 (0.5) |
|                                             | *Staphylococcus aureus*, blood + *Klebsiella* spp., NBL + *Haemophilus* spp., NBL | 1 (0.5) |
| Blood + lung + deep                        | *Enterococcus faecium; Elizabethkingia microra*, bronchial aspirate        | 1 (0.5) |
| soft tissue                                |                                                                           |         |
| Blood + urine                              | *Facklamia hominis*, blood; *Escherichia coli*, urine                      | 1 (0.5) |
| Central nervous system                     | *Herpes simplex virus*                                                   | 1 (0.5) |
| Lung                                       | *Acinetobacter baumannii*, tracheal aspirate                              | 1 (0.5) |
|                                             | *Acinetobacter* spp., tracheal aspirate (n = 1) and sputum (n = 1)        | 2 (1.1) |
|                                             | *Candida albicans*, low-respiratory tract NOS                              | 2 (1.1) |
|                                             | *Candida* spp., sputum                                                    | 1 (0.5) |
|                                             | *Citrobacter* spp., *Pseudomonas aeruginosa*, and *Herpes simplex virus*, bronchial aspirate | 1 (0.5) |
|                                             | *Corynebacterium striatum; Bordetella bronchiseptica*, bronchial aspirate  | 1 (0.5) |
|                                             | *Klebsiella pneumoniae; Staphylococcus aureus*, tracheal aspirate         | 1 (0.5) |
|                                             | *Klebsiella* spp., NBL                                                    | 1 (0.5) |
|                                             | *Klebsiella varicola; Candida albicans*, tracheal aspirate                | 1 (0.5) |
|                                             | *Pseudomonas aeruginosa*, tracheal aspirate                               | 2 (1.1) |
|                                             | *Stenotrophomonas maltophilia*, tracheal aspirate (n = 1) and sputum (n = 1) | 2 (1.1) |
|                                             | Unspecified yeasts, bronchial aspirate                                    | 1 (0.5) |
| Urinary tract                              | *Citrobacter amalonaticus*                                                | 1 (0.5) |
|                                             | *Enterococcus faecium*                                                   | 1 (0.5) |
| Total                                      |                                                                           | 40 (21.5) |

*NBL, nondirected bronchial lavage; NOS, not otherwise specified*
**Appendix Table 7.** Other conditions and exposures of 186 patients with coronavirus disease–associated pulmonary aspergillosis, March–August 2020

| Condition                                                                 | no. (%) |
|---------------------------------------------------------------------------|---------|
| Acute renal failure requiring dialysis                                   | 13 (7.0) |
| Sepsis                                                                   | 10 (5.4) |
| Acute liver failure                                                      | 9 (4.8)  |
| Lymphopenia                                                              | 8 (4.3)  |
| Hypothyroidism                                                           | 7 (3.8)  |
| Rheumatic or autoimmune disorder                                         | 7 (3.8)  |
| Ex-smoker                                                                | 6 (3.2)  |
| Smoker                                                                   | 6 (3.2)  |
| Thrombocytopenia                                                         | 6 (3.2)  |
| Septic shock                                                             | 4 (2.2)  |
| Benign prostatic hypertrophy                                             | 3 (1.6)  |
| Chronic liver failure                                                    | 3 (1.6)  |
| Non-ST segment elevation myocardial infarction                           | 3 (1.6)  |
| Acute renal failure requiring renal substitution                         | 2 (1.1)  |
| Chronic renal failure requiring dialysis                                 | 2 (1.1)  |
| Depression                                                               | 2 (1.1)  |
| Exposure to fungicides or manipulation of organic matter possibly containing triazole-resistant isolates of *Aspergillus fumigatus* | 2 (1.1) |
| History of pulmonary tuberculosis                                       | 2 (1.1)  |
| Multiorgan dysfunction syndrome                                          | 2 (1.1)  |
| Liver failure not otherwise specified                                   | 2 (1.1)  |
| Psychiatric disorder                                                    | 2 (1.1)  |
| Alcoholism                                                               | 1 (0.5)  |
| Aneurysm coiling right arteria vertebralis                               | 1 (0.5)  |
| Atrial myxoma                                                            | 1 (0.5)  |
| CD8+ T-cell lymphocytosis                                                | 1 (0.5)  |
| Contact with a patient with coronavirus disease                          | 1 (0.5)  |
| Cured thyroid cancer                                                     | 1 (0.5)  |
| Dementia                                                                 | 1 (0.5)  |
| Depression                                                               | 1 (0.5)  |
| Epilepsy                                                                 | 1 (0.5)  |
| Flavectomy and nucleotomy                                                | 1 (0.5)  |
| Gas gangrene                                                             | 1 (0.5)  |
| Glaucoma                                                                 | 1 (0.5)  |
| Hospital-acquired pneumonia                                             | 1 (0.5)  |
| Hypercholesterinemia                                                    | 1 (0.5)  |
| Hyperkalemia                                                             | 1 (0.5)  |
| Hyperparathyroidism secondary to chronic kidney disease                  | 1 (0.5)  |
| Hyperthyroidism                                                          | 1 (0.5)  |
| Hypercholesterolemia                                                    | 1 (0.5)  |
| Hyperlipidemia                                                           | 1 (0.5)  |
| Laparoscopic cholecystectomy for cholecystitis                           | 1 (0.5)  |
| Mastoiditis                                                              | 1 (0.5)  |
| Osteopenia                                                               | 1 (0.5)  |
| Polyneuropathy                                                           | 1 (0.5)  |
| Posterior reversible encephalopathy syndrome                            | 1 (0.5)  |
| Previous hepatitis B                                                     | 1 (0.5)  |
| Reactivation of cytomegalovirus                                          | 1 (0.5)  |
| Recent stroke                                                            | 1 (0.5)  |
| Sinusitis                                                                | 1 (0.5)  |
| Sleep apnea syndrome                                                    | 1 (0.5)  |
| Stenosis of the left internal carotid artery                            | 1 (0.5)  |
| Suspected pulmonary fibrosis                                             | 1 (0.5)  |
| Thyroidectomy                                                            | 1 (0.5)  |
| Umbilical hernia                                                         | 1 (0.5)  |
| Vertebral disc herniation left L4/5                                      | 1 (0.5)  |
| **Total**                                                                | 67 (36.0)|
### Appendix Table 8. Distribution of patients with coronavirus disease–associated pulmonary aspergillosis, March–August 2020

| Country     | FungiScope | FungiScope + Literature | Literature | Total, no. (%) |
|-------------|------------|------------------------|------------|----------------|
| Argentina   | 1 (0.5)    | 1 (0.5)                | 1 (0.5)    |                |
| Australia   | 1 (0.5)    | 1 (0.5)                | 1 (0.5)    |                |
| Austria     | 1 (0.5)    | 1 (0.5)                | 1 (0.5)    |                |
| Belgium     | 4 (2.2)    | 4 (2.2)                | 8 (4.3)    |                |
| Brazil      | 2 (1.1)    | 1 (0.5)                | 3 (1.6)    |                |
| Denmark     | 2 (1.1)    | 2 (1.1)                | 2 (1.1)    |                |
| France      | 18 (9.7)   | 9 (4.8)                | 12 (6.5)   | 39 (21.0)      |
| Germany     | 17 (9.1)   | 4 (2.2)                | 2 (1.1)    | 23 (12.4)      |
| Ireland     | 1 (0.5)    | 1 (0.5)                | 1 (0.5)    |                |
| Italy       | 4 (2.2)    | 30 (16.1)              | 2 (1.1)    | 36 (19.4)      |
| Mexico      | 6 (3.2)    |                        |            | 6 (3.2)        |
| Netherlands | 3 (1.6)    | 11 (5.9)               | 14 (7.5)   |                |
| Pakistan    | 9 (4.8)    | 9 (4.8)                |            |                |
| Qatar       | 2 (1.1)    | 2 (1.1)                |            |                |
| Spain       | 3 (1.6)    | 23 (12.4)              | 3 (1.6)    | 26 (14.0)      |
| Switzerland |            |                        | 3 (1.6)    |                |
| United Kingdom |        | 11 (5.9)               | 11 (5.9)   |                |
| Total       | 57 (30.6)  | 67 (36.0)              | 62 (33.3)  | 186 (100.0)    |